The genomic complexity of primary human prostate cancer

Nature

Volumn 470, Issue 7333, 2011, Pages 214-220

  Berger, Michael F ^a,l   Lawrence, Michael S ^a   Demichelis, Francesca ^b   Drier, Yotam ^c   Cibulskis, Kristian ^a   Sivachenko, Andrey Y ^a   Sboner, Andrea ^d   Esgueva, Raquel ^b   Pflueger, Dorothee ^b   Sougnez, Carrie ^a   Onofrio, Robert ^a   Carter, Scott L ^a   Park, Kyung ^b   Habegger, Lukas ^d   Ambrogio, Lauren ^a   Fennell, Timothy ^a   Parkin, Melissa ^a   Saksena, Gordon ^a   Voet, Douglas ^a   Ramos, Alex H ^a,e   Pugh, Trevor J ^a,e,f   Wilkinson, Jane ^a   Fisher, Sheila ^a   Winckler, Wendy ^a   Mahan, Scott ^a   Ardlie, Kristin ^a   Baldwin, Jennifer ^a   Simons, Jonathan W ^g   Kitabayashi, Naoki ^b   MacDonald, Theresa Y ^b   Kantoff, Philip W ^e,f   Chin, Lynda ^a,e,f   Gabriel, Stacey B ^a   Gerstein, Mark B ^d,h   Golub, Todd R ^a,f,i   Meyerson, Matthew ^a,e,f   Tewari, Ashutosh ^j   Lander, Eric S ^a,e,k   Getz, Gad ^a   Rubin, Mark A ^b   Garraway, Levi A ^a,e,f   more..

^a BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^d YALE UNIVERSITY   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g Prostate Cancer Foundation   (United States)

^h Yale University   (United States)

ⁱ HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^j NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^k WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^l MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; DNA;

ABNORMALITY; CAUSE OF DEATH; GENETIC ANALYSIS; GENOMICS; PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BINDING SITE; BREAST CANCER; CANCER MORTALITY; CHROMATIN IMMUNOPRECIPITATION; DNA BINDING; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GENOMICS; HUMAN; LUNG SMALL CELL CANCER; MALE; MELANOMA; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE TUMOR; SOLID TUMOR; TRANSCRIPTION REGULATION; TUMOR GENE;

CARRIER PROTEINS; CASE-CONTROL STUDIES; CELL ADHESION MOLECULES; CHROMATIN; CHROMOSOME ABERRATIONS; CHROMOSOME BREAKPOINTS; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, HUMAN; HUMANS; MALE; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; RECOMBINATION, GENETIC; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 79951497419     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature09744     Document Type: Article

References (50)

1. Jemal, A., Siegel, R., Xu, J. & Ward, E. Cancer statistics, 2010. CA Cancer J. Clin. 60, 277-300 (2010).
2. Tomlins, S. A. et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644-648 (2005). (Pubitemid 41528150)
3. Tomlins, S. A. et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 448, 595-599 (2007). (Pubitemid 47206938)
4. Helgeson, B. E. et al. Characterization ofTMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res. 68, 73-80 (2008). (Pubitemid 351380107)
5. Tomlins, S. A. et al. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res. 66, 3396-3400 (2006).
6. Li, J. et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275, 1943-1947 (1997). (Pubitemid 27148818)
7. Visakorpi, T. et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nature Genet. 9, 401-406 (1995).
8. Taylor, B. S. et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11-22 (2010).
9. Tran, C. et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324, 787-790 (2009).
10. Attard, G. et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J. Clin. Oncol. 26, 4563-4571 (2008).
11. Palanisamy, N. et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nature Med. 16, 793-798 (2010).
12. Krzywinski, M. et al. Circos: an information aesthetic for comparative genomics. Genome Res. 19, 1639-1645 (2009).
13. Ley, T. J. et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 456, 66-72 (2008).
14. Shah, S. P. et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 461, 809-813 (2009).
15. Mardis, E. R. et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N. Engl. J. Med. 361, 1058-1066 (2009).
16. Ding, L. et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464, 999-1005 (2010).
17. Pleasance, E. D. et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 463, 184-190 (2010).
18. Pleasance, E. D. et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 463, 191-196 (2010).
19. Berger, M. F. et al. Integrative analysis of the melanoma transcriptome. Genome Res. 20, 413-427 (2010).
20. Kwon, J. E. et al. BTB domain-containing speckle-type POZ protein (SPOP) serves as an adaptor of Daxx for ubiquitination by Cul3-based ubiquitin ligase. J. Biol. Chem. 281, 12664-12672 (2006).
21. Kan, Z. et al. Diverse somaticmutation patterns and pathway alterations in human cancers. Nature 466, 869-873 (2010).
22. Gaspar-Maia, A. et al. Chd1 regulates open chromatin and pluripotency of embryonic stem cells. Nature 460, 863-868 (2009).
23. Zhang, C.L., McKinsey, T.A. & Olson, E. N. Associationof class II histone deacetylases with heterochromatin protein 1: potential role for histone methylation in control of muscle differentiation. Mol. Cell. Biol. 22, 7302-7312 (2002).
24. Bagchi, A. et al. CHD5 is a tumor suppressor at human 1p36. Cell 128, 459-475 2007. (Pubitemid 46198889)
25. Pearl, L. H., Prodromou, C. & Workman, P. The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem. J. 410, 439-453 (2008). (Pubitemid 351429015)
26. Kantoff, P. W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411-422 (2010).
27. Kantoff, P. W. et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castrationresistant prostate cancer. J. Clin. Oncol. 28, 1099-1105 (2010).
28. Stephens, P. J. et al. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 462, 1005-1010 (2009).
29. Barbie, D. A. et al. Systematic RNA interference reveals that oncogenic KRASdriven cancers require TBK1. Nature 462, 108-112 (2009).
30. Osborne, C. S. et al. Active genes dynamically colocalize to shared sites of ongoing transcription. Nature Genet. 36, 1065-1071 (2004). (Pubitemid 41184467)
31. Lin, C. et al. Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell 139, 1069-1083 (2009).
32. Mani, R. S. et al. Induced chromosomal proximity and gene fusions in prostate cancer. Science 326, 1230 (2009).
33. Haffner, M. C. et al. Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nature Genet. 42, 668-675 (2010).
34. Lieberman-Aiden, E. et al. Comprehensive mapping of long-range interactions reveals folding principles of the human genome. Science 326, 289-293 (2009).
35. Yu, J. et al. An integrated network of androgen receptor, polycomb, andTMPRSS2- ERGgene fusions in prostate cancer progression. CancerCell17, 443-454(2010).
36. Lin, B. et al. Integrated expression profiling and ChIP-seq analyses of the growth inhibition response programof the androgen receptor. PLoSONE 4, e6589 (2009).
37. Birney, E. et al. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 447, 799-816 (2007). (Pubitemid 46920138)
38. Lee, W. et al. Themutation spectrumrevealed by paired genomesequences froma lung cancer patient. Nature 465, 473-477 (2010).
39. Krum, S. A. et al. Unique ERa cistromes control cell type-specific gene regulation. Mol. Endocrinol. 22, 2393-2406 (2008).
40. Yang, Y., Sterling, J., Storici, F., Resnick, M. A. & Gordenin, D. A. Hypermutability of damaged single-strand DNA formed at double-strand breaks and uncapped telomeres in yeast Saccharomyces cerevisiae. PLoS Genet. 4, e1000264 (2008).
41. Beroukhim, R. et al. The landscape of somatic copy-number alteration across human cancers. Nature 463, 899-905 (2010).
42. Bignell, G. R. et al. Signatures of mutation and selection in the cancer genome. Nature 463, 893-898 (2010).
43. Wu, X. et al. Evidence for regulation of the PTENtumor suppressor by amembranelocalized multi-PDZ domain containing scaffold protein MAGI-2. Proc. Natl Acad. Sci. USA 97, 4233-4238 (2000). (Pubitemid 30226116)
44. Vazquez, F. et al. Phosphorylation of the PTEN tail acts as an inhibitory switch by preventingits recruitment into a protein complex. J. Biol. Chem. 276, 48627-48630 2001.
45. Sjoblom, T. et al. The consensus coding sequences of human breast and colorectal cancers. Science 314, 268-274 (2006). (Pubitemid 44571966)
46. Parsons, D. W. et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1807-1812 (2008).
47. The Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068 (2008).
48. Carver, B. S. et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nature Genet. 41, 619-624 (2009).
49. King, J. C. et al. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nature Genet. 41, 524-526 (2009).
50. Han, B. et al. Fluorescence in situ hybridization study shows association of PTEN deletion withERGrearrangementduringprostate cancer progression.Mod. Pathol. 22, 1083-1093 (2009).